Is This One Drug Enough To Revive Hope In Eli Lilly and Company's Pipeline?

Published: Mar 05, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Eli Lilly & Co snagged a win (or at least avoided a loss) this week, announcing that its projected blockbuster GLP-1 agonist diabetes medication dulaglutide was comparable to current lead treatment Victoza (liraglutide) by Novo Nordisk .

Help employers find you! Check out all the jobs and post your resume.

Back to news